Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
China has always been believed to be the land of promise for multinational pharmaceutical companies. However, up until recently many organisations have struggled to see a return on their investments. That may all be set to change though.
The country’s recent 2020 healthcare reforms aim to rapidly increase the pace of new drug approvals and fast track innovative treatments, opening up a whole new world of opportunities for the pharmaceutical industry.
Register now for our next live webinar in which emerging markets experts Marc Yates and Helen Ansell will explore China’s evolving healthcare environment, highlight the key changes affecting pharma and show you how to  build the market understanding required to launch a brand effectively in this exciting region.
When: Tuesday 16th April 2019Â
Time: 10:00 EST/ 15:00 GMT / 16:00 CEST
Register now to secure your place »
China’s key growth factors:
Fast track approvals: So far, over 180 foreign pharma products have been granted priority review and will likely hit the market within the next few years.
From an ability to pay to willingness to pay: By 2022 more than half of the urban population will be defined as upper middle class and as incomes rise so does willingness to pay for quality healthcare.
Shifting disease patterns:Â Diseases of affluence are also on the rise and the benefits of urban life have resulted in an aging population and an explosion in age-related conditions.
What are the key takeaways in this webinar?Â
1. China 101Â
An overview of the healthcare environment in China
2. What’s changed?
The key opportunities under China’s 2020 healthcare reform
3. Where to play? How to win?
Design an effective marketing strategy with insights that prepare you for optimal success.
4. Gain answers to your key questions
Start the conversation by submitting your questions in advance when you register.
Register now to secure your place »
If you are unable to attend but would like to view the recording, register now and we will send you a unique link to download it as soon as it is ready.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Infographic: LATAM
Latin AmericaThe LATAM regions largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With...
Infographic: RA market snapshot
An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...
Infographic: CEE
The Central and Eastern Europe region is home to over 145 million people and is a key global growth region. With pharmaceutical sales set to exceed $27bn in 2014, it...
Infographic: ASEAN-6
Home to over half a billion people, the ASEAN region constitutes the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an...
Infographic: HCV – The Roadblocks to Effective Treatment
Referencing data from our Living with HCV survey undertaken with patients in the US and China, this infographic explores the roadblocks encountered on the path to effective and compliant treatment.Hepatitis C is...
Turkey: Identifying the Growth Drivers
Published in eye for pharma 3 April by Marc Yates
Article: The Patient Abroad
Published in Medical Marketing & Media March 2015
A guide to measuring and tracking brand KPIs
Dr Allison Fleetwood, Director of Therapy Watch, alongside Associate Director Jennifer Redfearn, recently delivered a workshop on measuring and tracking brand KPIs as part of the BHBIA training programme (www.bhbia.org.uk).
Electronic medical records and doctor/patient communication
View from the US: When I talk to family members or friends who are physicians these days, I hear a lot of complaints.
Statistics and bikinis – 2 men united
I want to write today about 2 men that between them have reminded me of a fine line that we have to tread every time we analyse a dataset...